A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer.
Tiffany M JuarezJaya M GillAnnie HengJose A CarrilloNaveed WagleNatsuko NomuraMinhdan NguyenJudy TruongLucia DobrawaWalavan SivakumarGarni BarkhoudarianDaniel F KellySantosh KesariPublished in: Neuro-oncology advances (2024)
Afatinib taken orally was safe and well-tolerated up to 280 mg every 7 days in brain cancer patients.
Keyphrases
- resting state
- white matter
- multiple sclerosis
- papillary thyroid
- epidermal growth factor receptor
- advanced non small cell lung cancer
- functional connectivity
- cerebral ischemia
- squamous cell
- open label
- randomized controlled trial
- squamous cell carcinoma
- clinical trial
- brain injury
- young adults
- subarachnoid hemorrhage
- blood brain barrier
- study protocol